Expleo Solutions Limited (EXPLEOSOL.NS) Stock Competitors & Peer Comparison
See (EXPLEOSOL.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Information Technology Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EXPLEOSOL.NS | ₹793.40 | -3.71% | 12.3B | 9.93 | ₹79.92 | N/A |
| TCS.NS | ₹2,153.90 | +0.13% | 7.8T | 15.82 | ₹136.11 | +6.51% |
| TCS.BO | ₹2,153.90 | +0.20% | 7.8T | 15.84 | ₹135.97 | +6.51% |
| INFY.NS | ₹1,145.30 | -2.97% | 4.6T | 15.07 | ₹76.01 | +3.81% |
| INFY.BO | ₹1,145.05 | -3.00% | 4.6T | 16.42 | ₹69.73 | +3.81% |
| HCLTECH.BO | ₹1,132.05 | -1.22% | 3.1T | 18.46 | ₹61.32 | +5.23% |
| HCLTECH.NS | ₹1,132.10 | -1.24% | 3.1T | 18.45 | ₹61.36 | +5.23% |
| WIPRO.NS | ₹178.93 | -1.51% | 1.9T | 14.25 | ₹12.56 | +6.05% |
| WIPRO.BO | ₹178.95 | -1.54% | 1.9T | 14.25 | ₹12.56 | +6.05% |
| LTIM.NS | ₹4,535.00 | +2.08% | 1.3T | 28.28 | ₹160.34 | +1.65% |
Stock Comparison
EXPLEOSOL.NS vs TCS.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, TCS.NS has a market cap of 7.8T. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while TCS.NS trades at ₹2,153.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas TCS.NS's P/E ratio is 15.82. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to TCS.NS's ROE of +0.46%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to TCS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check TCS.NS's competition here
EXPLEOSOL.NS vs TCS.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, TCS.BO has a market cap of 7.8T. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while TCS.BO trades at ₹2,153.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas TCS.BO's P/E ratio is 15.84. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to TCS.BO's ROE of +0.46%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to TCS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check TCS.BO's competition here
EXPLEOSOL.NS vs INFY.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, INFY.NS has a market cap of 4.6T. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while INFY.NS trades at ₹1,145.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas INFY.NS's P/E ratio is 15.07. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to INFY.NS's ROE of +0.32%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to INFY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check INFY.NS's competition here
EXPLEOSOL.NS vs INFY.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, INFY.BO has a market cap of 4.6T. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while INFY.BO trades at ₹1,145.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas INFY.BO's P/E ratio is 16.42. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to INFY.BO's ROE of +0.32%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to INFY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check INFY.BO's competition here
EXPLEOSOL.NS vs HCLTECH.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, HCLTECH.BO has a market cap of 3.1T. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while HCLTECH.BO trades at ₹1,132.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas HCLTECH.BO's P/E ratio is 18.46. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to HCLTECH.BO's ROE of +0.23%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to HCLTECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check HCLTECH.BO's competition here
EXPLEOSOL.NS vs HCLTECH.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, HCLTECH.NS has a market cap of 3.1T. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while HCLTECH.NS trades at ₹1,132.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas HCLTECH.NS's P/E ratio is 18.45. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to HCLTECH.NS's ROE of +0.23%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to HCLTECH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check HCLTECH.NS's competition here
EXPLEOSOL.NS vs WIPRO.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, WIPRO.NS has a market cap of 1.9T. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while WIPRO.NS trades at ₹178.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas WIPRO.NS's P/E ratio is 14.25. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to WIPRO.NS's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to WIPRO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check WIPRO.NS's competition here
EXPLEOSOL.NS vs WIPRO.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, WIPRO.BO has a market cap of 1.9T. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while WIPRO.BO trades at ₹178.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas WIPRO.BO's P/E ratio is 14.25. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to WIPRO.BO's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to WIPRO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check WIPRO.BO's competition here
EXPLEOSOL.NS vs LTIM.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, LTIM.NS has a market cap of 1.3T. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while LTIM.NS trades at ₹4,535.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas LTIM.NS's P/E ratio is 28.28. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to LTIM.NS's ROE of +0.21%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to LTIM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check LTIM.NS's competition here
EXPLEOSOL.NS vs TECHM.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, TECHM.NS has a market cap of 1.3T. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while TECHM.NS trades at ₹1,478.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas TECHM.NS's P/E ratio is 27.33. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to TECHM.NS's ROE of +0.17%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to TECHM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check TECHM.NS's competition here
EXPLEOSOL.NS vs TECHM.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, TECHM.BO has a market cap of 1.3T. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while TECHM.BO trades at ₹1,478.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas TECHM.BO's P/E ratio is 28.35. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to TECHM.BO's ROE of +0.17%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to TECHM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check TECHM.BO's competition here
EXPLEOSOL.NS vs LTIM.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, LTIM.BO has a market cap of 1.2T. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while LTIM.BO trades at ₹3,943.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas LTIM.BO's P/E ratio is 24.77. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to LTIM.BO's ROE of +0.21%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to LTIM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check LTIM.BO's competition here
EXPLEOSOL.NS vs LTM.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, LTM.NS has a market cap of 1.2T. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while LTM.NS trades at ₹3,944.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas LTM.NS's P/E ratio is 23.33. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to LTM.NS's ROE of +0.21%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to LTM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check LTM.NS's competition here
EXPLEOSOL.NS vs PERSISTENT.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, PERSISTENT.NS has a market cap of 769.9B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while PERSISTENT.NS trades at ₹4,928.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas PERSISTENT.NS's P/E ratio is 41.40. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to PERSISTENT.NS's ROE of +0.25%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to PERSISTENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check PERSISTENT.NS's competition here
EXPLEOSOL.NS vs PERSISTENT.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, PERSISTENT.BO has a market cap of 769.2B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while PERSISTENT.BO trades at ₹4,931.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas PERSISTENT.BO's P/E ratio is 44.54. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to PERSISTENT.BO's ROE of +0.25%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to PERSISTENT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check PERSISTENT.BO's competition here
EXPLEOSOL.NS vs COFORGE.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, COFORGE.NS has a market cap of 471.1B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while COFORGE.NS trades at ₹1,402.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas COFORGE.NS's P/E ratio is 32.05. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to COFORGE.NS's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to COFORGE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check COFORGE.NS's competition here
EXPLEOSOL.NS vs COFORGE.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, COFORGE.BO has a market cap of 470.7B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while COFORGE.BO trades at ₹1,401.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas COFORGE.BO's P/E ratio is 32.02. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to COFORGE.BO's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to COFORGE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check COFORGE.BO's competition here
EXPLEOSOL.NS vs MPHASIS.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, MPHASIS.BO has a market cap of 438.7B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while MPHASIS.BO trades at ₹2,298.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas MPHASIS.BO's P/E ratio is 24.37. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to MPHASIS.BO's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to MPHASIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check MPHASIS.BO's competition here
EXPLEOSOL.NS vs MPHASIS.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, MPHASIS.NS has a market cap of 438.5B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while MPHASIS.NS trades at ₹2,297.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas MPHASIS.NS's P/E ratio is 24.35. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to MPHASIS.NS's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to MPHASIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check MPHASIS.NS's competition here
EXPLEOSOL.NS vs LTTS.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, LTTS.NS has a market cap of 353B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while LTTS.NS trades at ₹3,328.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas LTTS.NS's P/E ratio is 28.73. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to LTTS.NS's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to LTTS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check LTTS.NS's competition here
EXPLEOSOL.NS vs LTTS.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, LTTS.BO has a market cap of 353B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while LTTS.BO trades at ₹3,327.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas LTTS.BO's P/E ratio is 28.78. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to LTTS.BO's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to LTTS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check LTTS.BO's competition here
EXPLEOSOL.NS vs HEXT.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, HEXT.NS has a market cap of 314.1B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while HEXT.NS trades at ₹515.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas HEXT.NS's P/E ratio is 22.84. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to HEXT.NS's ROE of +0.23%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to HEXT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check HEXT.NS's competition here
EXPLEOSOL.NS vs TATATECH.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, TATATECH.NS has a market cap of 307.9B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while TATATECH.NS trades at ₹758.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas TATATECH.NS's P/E ratio is 56.20. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to TATATECH.NS's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to TATATECH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check TATATECH.NS's competition here
EXPLEOSOL.NS vs TATATECH.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, TATATECH.BO has a market cap of 307.5B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while TATATECH.BO trades at ₹758.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas TATATECH.BO's P/E ratio is 56.23. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to TATATECH.BO's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to TATATECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check TATATECH.BO's competition here
EXPLEOSOL.NS vs KPITTECH.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, KPITTECH.BO has a market cap of 199.8B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while KPITTECH.BO trades at ₹734.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas KPITTECH.BO's P/E ratio is 31.49. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to KPITTECH.BO's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to KPITTECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check KPITTECH.BO's competition here
EXPLEOSOL.NS vs KPITTECH.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, KPITTECH.NS has a market cap of 199.5B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while KPITTECH.NS trades at ₹732.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas KPITTECH.NS's P/E ratio is 31.51. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to KPITTECH.NS's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to KPITTECH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check KPITTECH.NS's competition here
EXPLEOSOL.NS vs REDINGTON.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, REDINGTON.NS has a market cap of 179.6B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while REDINGTON.NS trades at ₹229.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas REDINGTON.NS's P/E ratio is 12.05. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to REDINGTON.NS's ROE of +0.16%. Regarding short-term risk, EXPLEOSOL.NS is less volatile compared to REDINGTON.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check REDINGTON.NS's competition here
EXPLEOSOL.NS vs REDINGTON.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, REDINGTON.BO has a market cap of 179.3B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while REDINGTON.BO trades at ₹229.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas REDINGTON.BO's P/E ratio is 12.06. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to REDINGTON.BO's ROE of +0.16%. Regarding short-term risk, EXPLEOSOL.NS is less volatile compared to REDINGTON.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check REDINGTON.BO's competition here
EXPLEOSOL.NS vs FSL.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, FSL.NS has a market cap of 172.8B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while FSL.NS trades at ₹250.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas FSL.NS's P/E ratio is 26.18. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to FSL.NS's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to FSL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check FSL.NS's competition here
EXPLEOSOL.NS vs FSL.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, FSL.BO has a market cap of 172.8B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while FSL.BO trades at ₹248.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas FSL.BO's P/E ratio is 26.00. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to FSL.BO's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to FSL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check FSL.BO's competition here
EXPLEOSOL.NS vs HEXAWARE.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, HEXAWARE.NS has a market cap of 141.4B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while HEXAWARE.NS trades at ₹470.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas HEXAWARE.NS's P/E ratio is 22.98. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to HEXAWARE.NS's ROE of +0.25%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to HEXAWARE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check HEXAWARE.NS's competition here
EXPLEOSOL.NS vs ECLERX.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, ECLERX.NS has a market cap of 126.7B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while ECLERX.NS trades at ₹1,359.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas ECLERX.NS's P/E ratio is 18.27. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to ECLERX.NS's ROE of +0.29%. Regarding short-term risk, EXPLEOSOL.NS is less volatile compared to ECLERX.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check ECLERX.NS's competition here
EXPLEOSOL.NS vs ECLERX.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, ECLERX.BO has a market cap of 126.7B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while ECLERX.BO trades at ₹1,360.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas ECLERX.BO's P/E ratio is 18.27. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to ECLERX.BO's ROE of +0.29%. Regarding short-term risk, EXPLEOSOL.NS is less volatile compared to ECLERX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check ECLERX.BO's competition here
EXPLEOSOL.NS vs ZENSARTECH.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, ZENSARTECH.NS has a market cap of 103.7B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while ZENSARTECH.NS trades at ₹457.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas ZENSARTECH.NS's P/E ratio is 13.57. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to ZENSARTECH.NS's ROE of +0.18%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to ZENSARTECH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check ZENSARTECH.NS's competition here
EXPLEOSOL.NS vs ZENSARTECH.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, ZENSARTECH.BO has a market cap of 102.9B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while ZENSARTECH.BO trades at ₹457.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas ZENSARTECH.BO's P/E ratio is 14.19. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to ZENSARTECH.BO's ROE of +0.18%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to ZENSARTECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check ZENSARTECH.BO's competition here
EXPLEOSOL.NS vs BSOFT.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, BSOFT.NS has a market cap of 88.2B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while BSOFT.NS trades at ₹315.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas BSOFT.NS's P/E ratio is 17.07. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to BSOFT.NS's ROE of +0.14%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to BSOFT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check BSOFT.NS's competition here
EXPLEOSOL.NS vs BSOFT.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, BSOFT.BO has a market cap of 88.2B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while BSOFT.BO trades at ₹315.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas BSOFT.BO's P/E ratio is 17.06. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to BSOFT.BO's ROE of +0.14%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to BSOFT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check BSOFT.BO's competition here
EXPLEOSOL.NS vs SONATSOFTW.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, SONATSOFTW.BO has a market cap of 72.5B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while SONATSOFTW.BO trades at ₹261.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas SONATSOFTW.BO's P/E ratio is 15.63. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to SONATSOFTW.BO's ROE of +0.26%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to SONATSOFTW.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check SONATSOFTW.BO's competition here
EXPLEOSOL.NS vs SONATSOFTW.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, SONATSOFTW.NS has a market cap of 72.2B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while SONATSOFTW.NS trades at ₹261.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas SONATSOFTW.NS's P/E ratio is 15.58. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to SONATSOFTW.NS's ROE of +0.26%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to SONATSOFTW.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check SONATSOFTW.NS's competition here
EXPLEOSOL.NS vs RSYSTEMINT.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, RSYSTEMINT.BO has a market cap of 63.6B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while RSYSTEMINT.BO trades at ₹531.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas RSYSTEMINT.BO's P/E ratio is 106.05. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to RSYSTEMINT.BO's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to RSYSTEMINT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check RSYSTEMINT.BO's competition here
EXPLEOSOL.NS vs HAPPSTMNDS.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, HAPPSTMNDS.NS has a market cap of 52.4B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while HAPPSTMNDS.NS trades at ₹348.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas HAPPSTMNDS.NS's P/E ratio is 24.76. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to HAPPSTMNDS.NS's ROE of +0.13%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to HAPPSTMNDS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check HAPPSTMNDS.NS's competition here
EXPLEOSOL.NS vs HAPPSTMNDS.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, HAPPSTMNDS.BO has a market cap of 52.3B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while HAPPSTMNDS.BO trades at ₹348.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas HAPPSTMNDS.BO's P/E ratio is 24.71. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to HAPPSTMNDS.BO's ROE of +0.13%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to HAPPSTMNDS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check HAPPSTMNDS.BO's competition here
EXPLEOSOL.NS vs MASTEK.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, MASTEK.BO has a market cap of 49.2B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while MASTEK.BO trades at ₹1,587.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas MASTEK.BO's P/E ratio is 12.26. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to MASTEK.BO's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.NS is less volatile compared to MASTEK.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check MASTEK.BO's competition here
EXPLEOSOL.NS vs MASTEK.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, MASTEK.NS has a market cap of 49.1B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while MASTEK.NS trades at ₹1,583.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas MASTEK.NS's P/E ratio is 12.22. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to MASTEK.NS's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to MASTEK.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check MASTEK.NS's competition here
EXPLEOSOL.NS vs DATAMATICS.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, DATAMATICS.BO has a market cap of 45.8B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while DATAMATICS.BO trades at ₹767.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas DATAMATICS.BO's P/E ratio is 23.34. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to DATAMATICS.BO's ROE of +0.14%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to DATAMATICS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check DATAMATICS.BO's competition here
EXPLEOSOL.NS vs DATAMATICS.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, DATAMATICS.NS has a market cap of 45.3B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while DATAMATICS.NS trades at ₹766.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas DATAMATICS.NS's P/E ratio is 23.33. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to DATAMATICS.NS's ROE of +0.14%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to DATAMATICS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check DATAMATICS.NS's competition here
EXPLEOSOL.NS vs ASMTEC.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, ASMTEC.BO has a market cap of 38.9B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while ASMTEC.BO trades at ₹3,273.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas ASMTEC.BO's P/E ratio is 78.55. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to ASMTEC.BO's ROE of +0.26%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to ASMTEC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check ASMTEC.BO's competition here
EXPLEOSOL.NS vs CAMS.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, CAMS.NS has a market cap of 36.7B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while CAMS.NS trades at ₹741.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas CAMS.NS's P/E ratio is 38.80. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to CAMS.NS's ROE of +0.40%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to CAMS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check CAMS.NS's competition here
EXPLEOSOL.NS vs CAMS.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, CAMS.BO has a market cap of 36.7B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while CAMS.BO trades at ₹740.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas CAMS.BO's P/E ratio is 38.75. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to CAMS.BO's ROE of +0.40%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to CAMS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check CAMS.BO's competition here
EXPLEOSOL.NS vs CIGNITITEC.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, CIGNITITEC.BO has a market cap of 34.8B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while CIGNITITEC.BO trades at ₹1,265.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas CIGNITITEC.BO's P/E ratio is 11.58. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to CIGNITITEC.BO's ROE of +0.31%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to CIGNITITEC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check CIGNITITEC.BO's competition here
EXPLEOSOL.NS vs CIGNITITEC.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, CIGNITITEC.NS has a market cap of 34.7B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while CIGNITITEC.NS trades at ₹1,260.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas CIGNITITEC.NS's P/E ratio is 11.53. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to CIGNITITEC.NS's ROE of +0.31%. Regarding short-term risk, EXPLEOSOL.NS is less volatile compared to CIGNITITEC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check CIGNITITEC.NS's competition here
EXPLEOSOL.NS vs SASKEN.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, SASKEN.NS has a market cap of 34.3B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while SASKEN.NS trades at ₹2,261.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas SASKEN.NS's P/E ratio is 63.87. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to SASKEN.NS's ROE of +0.07%. Regarding short-term risk, EXPLEOSOL.NS is less volatile compared to SASKEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check SASKEN.NS's competition here
EXPLEOSOL.NS vs SASKEN.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, SASKEN.BO has a market cap of 34.3B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while SASKEN.BO trades at ₹2,268.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas SASKEN.BO's P/E ratio is 63.95. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to SASKEN.BO's ROE of +0.07%. Regarding short-term risk, EXPLEOSOL.NS is less volatile compared to SASKEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check SASKEN.BO's competition here
EXPLEOSOL.NS vs RPSGVENT.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, RPSGVENT.BO has a market cap of 28.7B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while RPSGVENT.BO trades at ₹868.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas RPSGVENT.BO's P/E ratio is -20.83. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to RPSGVENT.BO's ROE of -0.04%. Regarding short-term risk, EXPLEOSOL.NS is less volatile compared to RPSGVENT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check RPSGVENT.BO's competition here
EXPLEOSOL.NS vs RPSGVENT.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, RPSGVENT.NS has a market cap of 28.7B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while RPSGVENT.NS trades at ₹868.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas RPSGVENT.NS's P/E ratio is -20.84. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to RPSGVENT.NS's ROE of -0.04%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to RPSGVENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check RPSGVENT.NS's competition here
EXPLEOSOL.NS vs RSYSTEMS.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, RSYSTEMS.NS has a market cap of 28.5B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while RSYSTEMS.NS trades at ₹240.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas RSYSTEMS.NS's P/E ratio is 14.01. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to RSYSTEMS.NS's ROE of +0.26%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to RSYSTEMS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check RSYSTEMS.NS's competition here
EXPLEOSOL.NS vs RSYSTEMS.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, RSYSTEMS.BO has a market cap of 28.5B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while RSYSTEMS.BO trades at ₹240.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas RSYSTEMS.BO's P/E ratio is 16.12. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to RSYSTEMS.BO's ROE of +0.26%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to RSYSTEMS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check RSYSTEMS.BO's competition here
EXPLEOSOL.NS vs PROTEAN.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, PROTEAN.BO has a market cap of 24.5B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while PROTEAN.BO trades at ₹603.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas PROTEAN.BO's P/E ratio is 24.43. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to PROTEAN.BO's ROE of +0.10%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to PROTEAN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check PROTEAN.BO's competition here
EXPLEOSOL.NS vs PROTEAN.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, PROTEAN.NS has a market cap of 24.5B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while PROTEAN.NS trades at ₹602.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas PROTEAN.NS's P/E ratio is 24.42. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to PROTEAN.NS's ROE of +0.10%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to PROTEAN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check PROTEAN.NS's competition here
EXPLEOSOL.NS vs SAKSOFT.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, SAKSOFT.BO has a market cap of 18.4B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while SAKSOFT.BO trades at ₹142.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas SAKSOFT.BO's P/E ratio is 15.08. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to SAKSOFT.BO's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to SAKSOFT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check SAKSOFT.BO's competition here
EXPLEOSOL.NS vs SAKSOFT.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, SAKSOFT.NS has a market cap of 18.2B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while SAKSOFT.NS trades at ₹142.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas SAKSOFT.NS's P/E ratio is 13.96. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to SAKSOFT.NS's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to SAKSOFT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check SAKSOFT.NS's competition here
EXPLEOSOL.NS vs DSSL.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, DSSL.BO has a market cap of 17.5B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while DSSL.BO trades at ₹1,373.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas DSSL.BO's P/E ratio is 20.61. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to DSSL.BO's ROE of +0.32%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to DSSL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check DSSL.BO's competition here
EXPLEOSOL.NS vs DSSL.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, DSSL.NS has a market cap of 17.5B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while DSSL.NS trades at ₹1,374.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas DSSL.NS's P/E ratio is 20.64. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to DSSL.NS's ROE of +0.32%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to DSSL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check DSSL.NS's competition here
EXPLEOSOL.NS vs ACCELYA.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, ACCELYA.NS has a market cap of 16.7B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while ACCELYA.NS trades at ₹1,120.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas ACCELYA.NS's P/E ratio is 15.52. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to ACCELYA.NS's ROE of +0.35%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to ACCELYA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check ACCELYA.NS's competition here
EXPLEOSOL.NS vs ACCELYA.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, ACCELYA.BO has a market cap of 16.6B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while ACCELYA.BO trades at ₹1,108.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas ACCELYA.BO's P/E ratio is 15.35. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to ACCELYA.BO's ROE of +0.35%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to ACCELYA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check ACCELYA.BO's competition here
EXPLEOSOL.NS vs MMWL.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, MMWL.BO has a market cap of 14.4B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while MMWL.BO trades at ₹12.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas MMWL.BO's P/E ratio is 254.60. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to MMWL.BO's ROE of +0.05%. Regarding short-term risk, EXPLEOSOL.NS is less volatile compared to MMWL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check MMWL.BO's competition here
EXPLEOSOL.NS vs MCLOUD.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, MCLOUD.BO has a market cap of 14.3B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while MCLOUD.BO trades at ₹24.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas MCLOUD.BO's P/E ratio is 13.82. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to MCLOUD.BO's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to MCLOUD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check MCLOUD.BO's competition here
EXPLEOSOL.NS vs MCLOUD.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, MCLOUD.NS has a market cap of 14.3B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while MCLOUD.NS trades at ₹24.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas MCLOUD.NS's P/E ratio is 13.82. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to MCLOUD.NS's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to MCLOUD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check MCLOUD.NS's competition here
EXPLEOSOL.NS vs AURUM.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, AURUM.NS has a market cap of 14B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while AURUM.NS trades at ₹183.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas AURUM.NS's P/E ratio is 705.69. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to AURUM.NS's ROE of +0.00%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to AURUM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check AURUM.NS's competition here
EXPLEOSOL.NS vs AURUM.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, AURUM.BO has a market cap of 13.8B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while AURUM.BO trades at ₹181.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas AURUM.BO's P/E ratio is 697.31. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to AURUM.BO's ROE of +0.00%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to AURUM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check AURUM.BO's competition here
EXPLEOSOL.NS vs NINSYS.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, NINSYS.BO has a market cap of 13.2B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while NINSYS.BO trades at ₹709.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas NINSYS.BO's P/E ratio is 41.23. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to NINSYS.BO's ROE of +0.44%. Regarding short-term risk, EXPLEOSOL.NS is less volatile compared to NINSYS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check NINSYS.BO's competition here
EXPLEOSOL.NS vs NINSYS.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, NINSYS.NS has a market cap of 13.2B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while NINSYS.NS trades at ₹709.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas NINSYS.NS's P/E ratio is 41.08. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to NINSYS.NS's ROE of +0.42%. Regarding short-term risk, EXPLEOSOL.NS is less volatile compared to NINSYS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check NINSYS.NS's competition here
EXPLEOSOL.NS vs EXPLEOSOL.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, EXPLEOSOL.BO has a market cap of 12.4B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while EXPLEOSOL.BO trades at ₹796.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas EXPLEOSOL.BO's P/E ratio is 9.97. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to EXPLEOSOL.BO's ROE of +0.17%. Regarding short-term risk, EXPLEOSOL.NS is less volatile compared to EXPLEOSOL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check EXPLEOSOL.BO's competition here
EXPLEOSOL.NS vs ORIENTTECH.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, ORIENTTECH.NS has a market cap of 11.4B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while ORIENTTECH.NS trades at ₹249.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas ORIENTTECH.NS's P/E ratio is 251.67. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to ORIENTTECH.NS's ROE of +0.01%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to ORIENTTECH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check ORIENTTECH.NS's competition here
EXPLEOSOL.NS vs BGDL.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, BGDL.BO has a market cap of 10.1B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while BGDL.BO trades at ₹99.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas BGDL.BO's P/E ratio is -9930.00. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to BGDL.BO's ROE of +0.07%. Regarding short-term risk, EXPLEOSOL.NS is less volatile compared to BGDL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check BGDL.BO's competition here
EXPLEOSOL.NS vs 3IINFOTECH.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, 3IINFOTECH.BO has a market cap of 9.3B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while 3IINFOTECH.BO trades at ₹54.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas 3IINFOTECH.BO's P/E ratio is 111.67. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to 3IINFOTECH.BO's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to 3IINFOTECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check 3IINFOTECH.BO's competition here
EXPLEOSOL.NS vs XCHANGING.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, XCHANGING.BO has a market cap of 7.1B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while XCHANGING.BO trades at ₹63.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas XCHANGING.BO's P/E ratio is 11.82. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to XCHANGING.BO's ROE of +0.16%. Regarding short-term risk, EXPLEOSOL.NS is less volatile compared to XCHANGING.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check XCHANGING.BO's competition here
EXPLEOSOL.NS vs XCHANGING.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, XCHANGING.NS has a market cap of 7B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while XCHANGING.NS trades at ₹63.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas XCHANGING.NS's P/E ratio is 11.80. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to XCHANGING.NS's ROE of +0.16%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to XCHANGING.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check XCHANGING.NS's competition here
EXPLEOSOL.NS vs ADSL.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, ADSL.BO has a market cap of 6.7B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while ADSL.BO trades at ₹117.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas ADSL.BO's P/E ratio is 18.73. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to ADSL.BO's ROE of +0.06%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to ADSL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check ADSL.BO's competition here
EXPLEOSOL.NS vs VAKRANGEE.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, VAKRANGEE.BO has a market cap of 6.6B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while VAKRANGEE.BO trades at ₹6.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas VAKRANGEE.BO's P/E ratio is 61.20. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to VAKRANGEE.BO's ROE of +0.05%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to VAKRANGEE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check VAKRANGEE.BO's competition here
EXPLEOSOL.NS vs MINDTECK.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, MINDTECK.BO has a market cap of 6.6B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while MINDTECK.BO trades at ₹206.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas MINDTECK.BO's P/E ratio is 20.99. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to MINDTECK.BO's ROE of +0.11%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to MINDTECK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check MINDTECK.BO's competition here
EXPLEOSOL.NS vs ADSL.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, ADSL.NS has a market cap of 6.6B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while ADSL.NS trades at ₹117.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas ADSL.NS's P/E ratio is 18.73. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to ADSL.NS's ROE of +0.06%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to ADSL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check ADSL.NS's competition here
EXPLEOSOL.NS vs VAKRANGEE.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, VAKRANGEE.NS has a market cap of 6.6B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while VAKRANGEE.NS trades at ₹6.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas VAKRANGEE.NS's P/E ratio is 61.10. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to VAKRANGEE.NS's ROE of +0.05%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to VAKRANGEE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check VAKRANGEE.NS's competition here
EXPLEOSOL.NS vs MINDTECK.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, MINDTECK.NS has a market cap of 6.6B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while MINDTECK.NS trades at ₹206.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas MINDTECK.NS's P/E ratio is 20.97. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to MINDTECK.NS's ROE of +0.11%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to MINDTECK.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check MINDTECK.NS's competition here
EXPLEOSOL.NS vs ONWARDTEC.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, ONWARDTEC.NS has a market cap of 5.8B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while ONWARDTEC.NS trades at ₹252.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas ONWARDTEC.NS's P/E ratio is 12.96. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to ONWARDTEC.NS's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to ONWARDTEC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check ONWARDTEC.NS's competition here
EXPLEOSOL.NS vs ONWARDTEC.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, ONWARDTEC.BO has a market cap of 5.8B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while ONWARDTEC.BO trades at ₹252.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas ONWARDTEC.BO's P/E ratio is 12.91. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to ONWARDTEC.BO's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to ONWARDTEC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check ONWARDTEC.BO's competition here
EXPLEOSOL.NS vs TERASOFT.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, TERASOFT.NS has a market cap of 5.5B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while TERASOFT.NS trades at ₹437.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas TERASOFT.NS's P/E ratio is 22.07. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to TERASOFT.NS's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.NS is less volatile compared to TERASOFT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check TERASOFT.NS's competition here
EXPLEOSOL.NS vs TERASOFT.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, TERASOFT.BO has a market cap of 5.4B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while TERASOFT.BO trades at ₹435.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas TERASOFT.BO's P/E ratio is 21.99. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to TERASOFT.BO's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.NS is less volatile compared to TERASOFT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check TERASOFT.BO's competition here
EXPLEOSOL.NS vs DIGISPICE.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, DIGISPICE.BO has a market cap of 4.8B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while DIGISPICE.BO trades at ₹20.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas DIGISPICE.BO's P/E ratio is 22.22. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to DIGISPICE.BO's ROE of +0.09%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to DIGISPICE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check DIGISPICE.BO's competition here
EXPLEOSOL.NS vs DIGISPICE.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, DIGISPICE.NS has a market cap of 4.8B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while DIGISPICE.NS trades at ₹20.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas DIGISPICE.NS's P/E ratio is 21.87. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to DIGISPICE.NS's ROE of +0.09%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to DIGISPICE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check DIGISPICE.NS's competition here
EXPLEOSOL.NS vs INSPIRISYS.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, INSPIRISYS.BO has a market cap of 4.7B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while INSPIRISYS.BO trades at ₹118.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas INSPIRISYS.BO's P/E ratio is 12.08. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to INSPIRISYS.BO's ROE of +0.57%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to INSPIRISYS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check INSPIRISYS.BO's competition here
EXPLEOSOL.NS vs SILVERTUC.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, SILVERTUC.BO has a market cap of 4.7B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while SILVERTUC.BO trades at ₹184.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas SILVERTUC.BO's P/E ratio is 65.59. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to SILVERTUC.BO's ROE of +0.25%. Regarding short-term risk, EXPLEOSOL.NS is less volatile compared to SILVERTUC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check SILVERTUC.BO's competition here
EXPLEOSOL.NS vs SILVERTUC.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, SILVERTUC.NS has a market cap of 4.7B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while SILVERTUC.NS trades at ₹184.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas SILVERTUC.NS's P/E ratio is 65.35. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to SILVERTUC.NS's ROE of +0.25%. Regarding short-term risk, EXPLEOSOL.NS is less volatile compared to SILVERTUC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check SILVERTUC.NS's competition here
EXPLEOSOL.NS vs INSPIRISYS.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, INSPIRISYS.NS has a market cap of 4.6B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while INSPIRISYS.NS trades at ₹115.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas INSPIRISYS.NS's P/E ratio is 11.73. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to INSPIRISYS.NS's ROE of +0.57%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to INSPIRISYS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check INSPIRISYS.NS's competition here
EXPLEOSOL.NS vs CYBERTECH.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, CYBERTECH.NS has a market cap of 4.2B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while CYBERTECH.NS trades at ₹136.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas CYBERTECH.NS's P/E ratio is 13.96. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to CYBERTECH.NS's ROE of +0.14%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to CYBERTECH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check CYBERTECH.NS's competition here
EXPLEOSOL.NS vs CYBERTECH.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, CYBERTECH.BO has a market cap of 4.2B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while CYBERTECH.BO trades at ₹136.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas CYBERTECH.BO's P/E ratio is 13.96. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to CYBERTECH.BO's ROE of +0.14%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to CYBERTECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check CYBERTECH.BO's competition here
EXPLEOSOL.NS vs SIGMA.NS Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, SIGMA.NS has a market cap of 4.2B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while SIGMA.NS trades at ₹40.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas SIGMA.NS's P/E ratio is 17.49. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to SIGMA.NS's ROE of +0.40%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to SIGMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check SIGMA.NS's competition here
EXPLEOSOL.NS vs SIGMA.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, SIGMA.BO has a market cap of 4.1B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while SIGMA.BO trades at ₹40.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas SIGMA.BO's P/E ratio is 17.52. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to SIGMA.BO's ROE of +0.40%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to SIGMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check SIGMA.BO's competition here
EXPLEOSOL.NS vs XTGLOBAL.BO Comparison June 2026
EXPLEOSOL.NS plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.NS stands at 12.3B. In comparison, XTGLOBAL.BO has a market cap of 3.9B. Regarding current trading prices, EXPLEOSOL.NS is priced at ₹793.40, while XTGLOBAL.BO trades at ₹29.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.NS currently has a P/E ratio of 9.93, whereas XTGLOBAL.BO's P/E ratio is 34.79. In terms of profitability, EXPLEOSOL.NS's ROE is +0.17%, compared to XTGLOBAL.BO's ROE of +0.07%. Regarding short-term risk, EXPLEOSOL.NS is more volatile compared to XTGLOBAL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.NS.Check XTGLOBAL.BO's competition here